A detailed history of Everett Harris & CO transactions in Gilead Sciences, Inc. stock. As of the latest transaction made, Everett Harris & CO holds 2,027 shares of GILD stock, worth $236,713. This represents 0.0% of its overall portfolio holdings.

Number of Shares
2,027
Previous 2,052 1.22%
Holding current value
$236,713
Previous $229,000 2.18%
% of portfolio
0.0%
Previous 0.0%

Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2025

Aug 08, 2025

SELL
$96.91 - $113.0 $2,422 - $2,825
-25 Reduced 1.22%
2,027 $224,000
Q1 2025

May 12, 2025

BUY
$89.14 - $117.41 $182,915 - $240,925
2,052 New
2,052 $229,000
Q4 2023

Jan 18, 2024

SELL
$73.27 - $83.09 $1,831 - $2,077
-25 Reduced 0.86%
2,869 $232,000
Q3 2023

Oct 23, 2023

SELL
$73.94 - $80.67 $38,744 - $42,271
-524 Reduced 15.33%
2,894 $216,000
Q2 2023

Jul 26, 2023

BUY
$76.01 - $86.7 $2,964 - $3,381
39 Added 1.15%
3,418 $263,000
Q4 2022

Jan 20, 2023

BUY
$62.32 - $89.47 $210,579 - $302,319
3,379 New
3,379 $0

Others Institutions Holding GILD

About GILEAD SCIENCES, INC.


  • Ticker GILD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,253,369,984
  • Market Cap $146B
  • Description
  • Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...
More about GILD
Track This Portfolio

Track Everett Harris & CO Portfolio

Follow Everett Harris & CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Everett Harris & CO , based on Form 13F filings with the SEC.

News

Stay updated on Everett Harris & CO with notifications on news.